CO4480098A1 - Formulaciones de danofloxacina inyectable que comprenden un compuesto de cinc con un disolvente complementario . - Google Patents
Formulaciones de danofloxacina inyectable que comprenden un compuesto de cinc con un disolvente complementario .Info
- Publication number
- CO4480098A1 CO4480098A1 CO96066993A CO96066993A CO4480098A1 CO 4480098 A1 CO4480098 A1 CO 4480098A1 CO 96066993 A CO96066993 A CO 96066993A CO 96066993 A CO96066993 A CO 96066993A CO 4480098 A1 CO4480098 A1 CO 4480098A1
- Authority
- CO
- Colombia
- Prior art keywords
- conforming
- complementary solvent
- danofloxacin
- complementary
- solvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SOLUCIONES FARMACEUTICAS ACUOSAS ADECUADAS PARA INYECCION EN UN HUESPED, QUE TIENEN MEJORADA LA TOLERANCIA EN EL SITIO DE LA INYECCION, COMPRENDEN DANOFLOXACINA O SUS SALES FARMACEUTICAMENTE ACEP- TABLES Y UN COMPUESTO DE MAGNESIO O DE CINC. EL COMPUESTO DE CINC REQUIERE ADEMAS LA PRESENCIA DE UN DISOLVENTE COMPLEMENTARIO. ADECUADA EN UN HUESPED, QUE COMPRENDE DANOFLOXACI- NA O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES EN UNA CANTIDAD SUFICIENTE PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS Y, (1) UN COMPUESTO DE MAGNESIO O, (2) UN COMPUESTO DE CINC MEZCLADO CON UN DISOLVENTE COMPLEMENTARIO, ESTANDO PRESENTES DICHOS COMPUESTOS Y DICHO DISOLVENTE COMPLEMENTA- RIO EN CANTIDADES QUE SON SUFICIENTES PARA MEJORAR LA TOLERANCIA EN EL SITIO DE LA INYECCION. UNA CONFORME A LA REIVINDICACION 1, EN LA QUE DI- CHO COMPUESTO DE MAGNESIO ESTA PRESENTE JUNTO CON UN DISOLVENTE COMPLEMENTARIO. UNA CONFORME A LA REIVINDICACION 1 O 2, EN LA QUE DICHO DISOLVENTE COMPLEMENTARIO ES AL MENOS UNO DE 2-PIRROLIDONA, PROPILENGLICOL, POLIETILENGLICOL Y N-METIL PIRROLIDONA, CADA UNO DE ELLOS OPCIONAL- MENTE JUNTO CON POLIVINILPIRROLIDONA. UNA CONFORME A UNA CUALQUIERA DE LAS REIVINDICA- CIONES 1, 2 O 3, EN LA QUE DICHA SOLUCION CONTIENE ADEMAS UN ANTIOXIDANTE. UNA CONFORME A LA REIVINDICACION 4, EN LA QUE DI- CHO ANTIOXIDANTE ES FORMALDEHIDO SULFOXILATO SODI- CO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US905295P | 1995-12-21 | 1995-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4480098A1 true CO4480098A1 (es) | 1997-07-09 |
Family
ID=21735307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO96066993A CO4480098A1 (es) | 1995-12-21 | 1996-12-20 | Formulaciones de danofloxacina inyectable que comprenden un compuesto de cinc con un disolvente complementario . |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US5811130A (es) |
| EP (1) | EP0868183B1 (es) |
| JP (1) | JP3416145B2 (es) |
| KR (1) | KR100402570B1 (es) |
| CN (1) | CN1104899C (es) |
| AP (1) | AP706A (es) |
| AR (1) | AR005147A1 (es) |
| AT (1) | ATE212551T1 (es) |
| AU (1) | AU709474B2 (es) |
| BG (1) | BG63933B1 (es) |
| BR (1) | BR9612230A (es) |
| CA (1) | CA2239352C (es) |
| CO (1) | CO4480098A1 (es) |
| CZ (1) | CZ293747B6 (es) |
| DE (1) | DE69618987T2 (es) |
| DK (1) | DK0868183T3 (es) |
| DZ (1) | DZ2146A1 (es) |
| EG (1) | EG24071A (es) |
| ES (1) | ES2167609T3 (es) |
| GT (1) | GT199600098A (es) |
| HR (1) | HRP960607B1 (es) |
| HU (1) | HU227918B1 (es) |
| IL (1) | IL124454A (es) |
| IS (1) | IS2010B (es) |
| MA (1) | MA24035A1 (es) |
| MX (1) | MX9805026A (es) |
| MY (1) | MY117109A (es) |
| NO (1) | NO315734B1 (es) |
| NZ (2) | NZ320545A (es) |
| OA (1) | OA10697A (es) |
| PE (1) | PE25798A1 (es) |
| PL (1) | PL186795B1 (es) |
| PT (1) | PT868183E (es) |
| RS (1) | RS49523B (es) |
| RU (1) | RU2141827C1 (es) |
| SI (1) | SI0868183T1 (es) |
| SK (1) | SK284412B6 (es) |
| TN (1) | TNSN96163A1 (es) |
| TW (1) | TW449475B (es) |
| UA (1) | UA56151C2 (es) |
| WO (1) | WO1997023217A1 (es) |
| ZA (1) | ZA9610780B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID21415A (id) * | 1997-12-05 | 1999-06-10 | Upjohn Co | Senyawa-senyawa antibiotik magnesium quinolon |
| US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
| DE19937116A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| DE19937115A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon |
| EP1255565A1 (de) * | 2000-01-13 | 2002-11-13 | MERCK PATENT GmbH | Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler |
| CA2433037C (en) * | 2000-12-28 | 2010-12-21 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| BR0312111A (pt) * | 2002-06-26 | 2005-03-29 | Pharmacia Corp | Formulação estável, lìquida, parenteral de parecoxib |
| RU2007104026A (ru) * | 2004-07-02 | 2008-08-10 | Дайити Фармасьютикал Ко., Лтд. (JP) | Содержащая хинолон лекарственная композиция |
| US8524735B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| EP2594272B1 (en) * | 2005-05-18 | 2018-07-11 | Horizon Orphan LLC | Aerosolized fluoroquinolones and uses thereof |
| FR2896416B1 (fr) | 2006-01-24 | 2010-08-13 | Vetoquinol | Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine |
| CA2641827A1 (en) * | 2006-02-10 | 2007-08-16 | Pari Pharma Gmbh | Nebulised antibiotics for inhalation therapy |
| US20070197548A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone compositions |
| DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
| DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
| MX2007009796A (es) * | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| HUE050147T2 (hu) | 2008-10-07 | 2020-11-30 | Horizon Orphan Llc | Tüdõgyulladás csökkentése levofloxacin belélegzése útján |
| NO2344129T3 (es) | 2008-10-07 | 2018-07-21 | ||
| RU2563809C2 (ru) | 2009-09-04 | 2015-09-20 | Мпекс Фармасьютикалс, Инк. | Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| EP3305295A4 (en) | 2015-06-02 | 2019-02-20 | Kyorin Pharmaceutical Co., Ltd. | AQUEOUS MEDICINE |
| US10617684B2 (en) | 2015-06-02 | 2020-04-14 | Kyorin Pharmaceutical Co., Ltd. | Aqueous drug |
| EP3305296A4 (en) | 2015-06-02 | 2019-02-13 | Kyorin Pharmaceutical Co., Ltd. | AQUEOUS LIQUID FORMULATION |
| MX2019009572A (es) * | 2017-02-13 | 2019-10-02 | Bayer Animal Health Gmbh | Composicion liquida que contiene pradofloxacina. |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3517709A1 (de) * | 1985-01-05 | 1986-07-10 | Bayer Ag | Basische zubereitungen von chinoloncarbonsaeuren |
| JPS63188626A (ja) * | 1987-01-30 | 1988-08-04 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸の可溶化方法 |
| DE3902079A1 (de) * | 1988-04-15 | 1989-10-26 | Bayer Ag | I.m. injektionsformen von gyrase-inhibitoren |
| CA2072366C (en) * | 1989-12-29 | 2002-08-20 | Laman A. Al-Razzak | Carboxylic acid-metal ion-acid complexes |
| US5084276A (en) * | 1990-01-05 | 1992-01-28 | Abbott Laboratories | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation |
| ATE108649T1 (de) * | 1990-02-14 | 1994-08-15 | Takeda Chemical Industries Ltd | Brausemischung, deren herstellung sowie verwendung. |
| FR2665635A1 (fr) * | 1990-08-10 | 1992-02-14 | Merck Sharp & Dohme | Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation. |
| US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
| US5235054A (en) * | 1992-07-15 | 1993-08-10 | Pfizer Inc. | 3-carboxaldehyde substituted quinolines and naphthyridines |
| JPH0782141A (ja) * | 1993-09-17 | 1995-03-28 | Tanabe Seiyaku Co Ltd | 動物用注射剤 |
-
1996
- 1996-11-13 ES ES96935251T patent/ES2167609T3/es not_active Expired - Lifetime
- 1996-11-13 AT AT96935251T patent/ATE212551T1/de active
- 1996-11-13 HU HU9903726A patent/HU227918B1/hu unknown
- 1996-11-13 DK DK96935251T patent/DK0868183T3/da active
- 1996-11-13 DE DE69618987T patent/DE69618987T2/de not_active Expired - Lifetime
- 1996-11-13 JP JP52344797A patent/JP3416145B2/ja not_active Expired - Lifetime
- 1996-11-13 KR KR10-1998-0704719A patent/KR100402570B1/ko not_active IP Right Cessation
- 1996-11-13 IL IL12445496A patent/IL124454A/xx not_active IP Right Cessation
- 1996-11-13 SK SK807-98A patent/SK284412B6/sk not_active IP Right Cessation
- 1996-11-13 CZ CZ19981930A patent/CZ293747B6/cs not_active IP Right Cessation
- 1996-11-13 SI SI9630422T patent/SI0868183T1/xx unknown
- 1996-11-13 CN CN96199249A patent/CN1104899C/zh not_active Expired - Lifetime
- 1996-11-13 NZ NZ320545A patent/NZ320545A/xx not_active IP Right Cessation
- 1996-11-13 WO PCT/IB1996/001217 patent/WO1997023217A1/en active IP Right Grant
- 1996-11-13 PL PL96328001A patent/PL186795B1/pl unknown
- 1996-11-13 AU AU73289/96A patent/AU709474B2/en not_active Expired
- 1996-11-13 BR BR9612230A patent/BR9612230A/pt active IP Right Grant
- 1996-11-13 UA UA98063226A patent/UA56151C2/uk unknown
- 1996-11-13 CA CA002239352A patent/CA2239352C/en not_active Expired - Lifetime
- 1996-11-13 EP EP96935251A patent/EP0868183B1/en not_active Expired - Lifetime
- 1996-11-13 PT PT96935251T patent/PT868183E/pt unknown
- 1996-11-13 RU RU98111831A patent/RU2141827C1/ru active
- 1996-11-13 NZ NZ501160A patent/NZ501160A/en not_active IP Right Cessation
- 1996-11-15 TW TW085114021A patent/TW449475B/zh not_active IP Right Cessation
- 1996-12-10 PE PE1996000892A patent/PE25798A1/es not_active Application Discontinuation
- 1996-12-17 EG EG113496A patent/EG24071A/xx active
- 1996-12-18 DZ DZ960191A patent/DZ2146A1/fr active
- 1996-12-18 TN TNTNSN96163A patent/TNSN96163A1/fr unknown
- 1996-12-18 MA MA24427A patent/MA24035A1/fr unknown
- 1996-12-19 AR ARP960105774A patent/AR005147A1/es active IP Right Grant
- 1996-12-19 US US08/769,809 patent/US5811130A/en not_active Expired - Lifetime
- 1996-12-19 GT GT199600098A patent/GT199600098A/es unknown
- 1996-12-19 AP APAP/P/1996/000898A patent/AP706A/en active
- 1996-12-19 HR HR960607A patent/HRP960607B1/xx not_active IP Right Cessation
- 1996-12-20 CO CO96066993A patent/CO4480098A1/es unknown
- 1996-12-20 RS YU69096A patent/RS49523B/sr unknown
- 1996-12-20 ZA ZA9610780A patent/ZA9610780B/xx unknown
- 1996-12-20 MY MYPI96005411A patent/MY117109A/en unknown
-
1998
- 1998-05-25 IS IS4755A patent/IS2010B/is unknown
- 1998-06-12 OA OA9800082A patent/OA10697A/en unknown
- 1998-06-15 BG BG102542A patent/BG63933B1/bg unknown
- 1998-06-19 MX MX9805026A patent/MX9805026A/es unknown
- 1998-06-19 NO NO19982842A patent/NO315734B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4480098A1 (es) | Formulaciones de danofloxacina inyectable que comprenden un compuesto de cinc con un disolvente complementario . | |
| RU94033520A (ru) | Впрыскиваемый лецитиновый гель | |
| CY1118334T1 (el) | Χρηση δαπτομυκινης | |
| BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
| ATE156995T1 (de) | Zusammensetzung zur steigerung der hautdurchlässigkeit | |
| AR024516A1 (es) | Compuestos bi-aromaticos analogos de la vitamina d, su utilizacion, composicion farmaceutica y composicion cosmetica que comprenden al menos uno de dichos compuestos y utilizacion de dicha composicion cosmetica. | |
| MX9301929A (es) | Derivados de pirimidina y procedimientos para su preparacion. | |
| NO955361L (no) | Organiske aerogeler | |
| RU95110109A (ru) | Комплекс, содержащий аналог человеческого инсулина, и фармацевтическая композиция на его основе | |
| TR199901127T2 (xx) | Antibakteriyel etkili 6-O-ikameli ketolitler. | |
| ES2063033T3 (es) | Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. | |
| GT199100032A (es) | Compuestos y metodos sinergistico terapeuticos | |
| KR960701661A (ko) | AIDS치료용 약제학적 배합물중의 HIV프로테아제 억제제(HIV protease inhibitors in pharmaceutical combinations for the treament of AIDS) | |
| DE69434121D1 (de) | Pharmazeutische zusammensetzung zur immunstimulierenden therapie | |
| BR9904150A (pt) | Composições de proteìnas estabilizadas | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| DK98089D0 (da) | Medikament-lipid-systemer med lav toxicitet | |
| BR0009524A (pt) | Uso de um composto, e, composição farmacêutica ou veterinaria | |
| AR006523A1 (es) | Compuestos ciclicos, inhibidores de la adhesion | |
| EA200200995A1 (ru) | Применение композиций азалидных антибиотиков для лечения или предупреждения бактериальных или протозойных инфекций у млекопитающих | |
| ES2111163T3 (es) | Uso de fosfonatos para el tratamiento de la osteoporosis. | |
| CO5050328A1 (es) | Sistema solvente para la mejor penetracion de compuestos farmaceuticos | |
| ES2181849T3 (es) | Procedimiento para minimizar la perdida osea. | |
| ES2135342B1 (es) | Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. | |
| DE68917937D1 (de) | Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung. |